English  |  正體中文  |  简体中文  |  Items with full text/Total items : 6646/14523 (46%)
Visitors : 8079903      Online Users : 312
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.fy.edu.tw/ir/handle/987654321/8733


    Title: Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line.
    Authors: Kee-Lung Chang;Hsiao-Ling Cheng;Li-Wen Huang;Bau-Shan Hsieh;Yu-Chen Hu;Tsai-Tung Chih;Huey-Wen Shyu;Shu-Jem Su
    Contributors: 輔英科技大學 醫學檢驗生物技術系
    Keywords: Genistein;Terazosin;Prostate cancer;Apoptosis;Vascular endothelial growth factor (VEGF)
    Date: 2009-03-01
    Issue Date: 2010-11-03 15:44:21 (UTC+8)
    Abstract: Metastatic prostate cancer progresses from androgen-dependent to androgen-independent. Terazosin, a long-acting selective α1-adrenoreceptor antagonist, induces apoptosis of prostate cancer cells in an α1-adrenoreceptor-independent manner, while genistein, a major soy isoflavone, inhibits the growth of several types of cancer cells. The present study was designed to test the therapeutic potential of a combination of terazosin and genistein using a metastatic, hormone-independent prostatic cancer cell line, DU-145.

    Terazosin or genistein treatment inhibited the growth of DU-145 cells in a dose-dependent manner, whereas had no effect on normal prostate epithelial cells. Addition of 1 μg/ml of terazosin, which was inactive alone, augmented the growth inhibitory effect of 5 μg/ml of genistein. Co-treatment with terazosin resulted in the genistein-induced arrest of DU-145 cells in G2/M phase being overridden and an increase in apoptotic cells, as evidenced by procaspase-3 activation and PARP cleavage. The combination also caused a greater decrease in the levels of the apoptosis-regulating protein, Bcl-XL, and of VEGF165 and VEGF121 than genistein alone.

    In conclusion, the terazosin/genistein combination was more effective in inhibiting cell growth and VEGF expression as well as inducing apoptosis of the metastatic, androgen-independent prostate cancer cell line, DU-145, than either alone. The doses used in this study are in lower and nontoxic anticancer dosage range, suggesting this combination has potential for therapeutic use.
    Relation: Cancer Lett. 276(1),14-20
    Appears in Collections:[醫學檢驗生物技術系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML426View/Open


    All items in FYIR are protected by copyright, with all rights reserved.


    本網站典藏內容為學術研究目的之提供,請尊重著作權人之權益合理使用,請勿任意重製、轉貼、改作及散佈。

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback